Enthusiastic feed-back of nutraceutical industry at VENDORBRIEF presentation of Mythocondro® held last week during Supply Side West, in Las Vegas.
Prof. Nicola Volpi, Associate Professor of Biochemistry at the University of Modena and Reggio Emilia, Italy, one of the worldwide expert in the field of chondroitin sulfate (CS), gave a successful speech on the concerns of current industrial production of animal-derived chondroitin sulfate and introduced Mythocondro®, the pioneering ingredient developed by the Italian based company Gnosis, through an innovative fermentation technology.
Mythocondro® promises to resolve the long-standing acknowledged problem of poor quality and potential safety issues of animal-derived CS.
The speech was also the occasion to issue and present a book that describe and unlock the insights about this new Non-Animal Chondroitin Sulfate, with relevant effectiveness in joint disease.
Going inside the speech, Prof. Volpi offered a trip into chondroitin world with an extensive overview of the aetiopathogenesis of OA, of the current database of CS in the treatment of OA, the relative safety concerns of animal-derived sources and the relevant description and clinical evidence of Mythocondro®.
CS is a natural sulfated GAG which play a significant role in biological processes as it is abundantly distributed in humans, other mammals and invertebrates. Based on its structural diversity in chain length and sulfation patterns, CS provides specific biological functions in cell adhesion, morphogenesis, neural network formation and cell division.
Even if the clinical benefits of CS have been established by a large number of human trials it is also known that animal-derived chondroitin is now acknowledged within the nutraceuticals industry as one of the most adulterated supplements in the market. This poses serious concerns about the quality and the safety of the ingredient.
Animal CS safety concerns*
Animal CS supplied to the market is extracted from cartilaginous feedstocks using organic solvents, with purification processes that may cause chemical degradation/desulfation and loss of activity along with an uncontrolled and unreliable supply chain of CS raw materials].
Source material, manufacturing processes, the presence of contaminants and many other factors contribute to the quality, structure and physico-chemical properties of the final product and of the overall biological and pharmacological activities of this bioactive (macro)molecule